A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

NCT00982631 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced/Recurrent Breast Cancer
Endometrial Cancer
Ovarian Cancer

Interventions

DRUG: Temsirolimus/PLD

Sponsor

Radboud University Medical Center